약물 방출 풍선 시장 : 약제 유형, 제품 유형, 용도, 최종 사용자, 유통 채널별 예측(2026-2032년)

The Drug Eluting Balloon Market is projected to grow by USD 3.66 billion at a CAGR of 16.26% by 2032.

Drug Eluting Balloon Market Introduction

Drug eluting balloons, also known as drug-coated balloons, are catheter-based angioplasty devices that deliver an antiproliferative drug to the vessel wall without leaving a permanent implant. The technology is most established in peripheral artery disease, especially femoropopliteal lesions, and in selected coronary applications such as in-stent restenosis and small-vessel disease where avoiding additional metal layers can be clinically valuable.

The market is shaped by a strong evidence requirement because drug eluting balloon performance depends on drug choice, dose density, excipient chemistry, balloon transfer efficiency, lesion preparation, and operator technique. Randomized clinical studies, meta-analyses, and real-world registries have shown that effective drug-coated balloon platforms can reduce restenosis-related repeat procedures compared with plain balloon angioplasty in appropriate lesions, making the category strategically important for hospitals, ambulatory vascular centers, payers, and medical device manufacturers.

Transformative Shifts in the Drug Eluting Balloon Landscape

The drug eluting balloon landscape is moving from a single-product innovation story toward a broader vascular therapy platform. Paclitaxel-coated balloons built the commercial foundation because paclitaxel is lipophilic and transfers rapidly during short balloon inflation; however, manufacturers are now investing in sirolimus-coated balloon technologies to address safety perception, drug-release control, and use in more complex vascular beds.

Regulatory expectations have also transformed. The U.S. FDA updated its position in 2023, stating that available data did not support an excess late mortality risk for paclitaxel-coated devices, following years of additional follow-up and patient-level analyses. At the same time, Europe's Medical Device Regulation has increased clinical evidence, technical documentation, and post-market surveillance obligations, pushing companies to build stronger trial, registry, and pharmacovigilance systems.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is becoming a cumulative enabler across the drug eluting balloon value chain rather than a standalone device feature. In clinical practice, AI-assisted angiographic and intravascular imaging analytics can support lesion measurement, calcification assessment, vessel sizing, dissections, recoil, and post-angioplasty result evaluation, all of which influence drug transfer and long-term patency.

For manufacturers, AI can improve coating process control, defect detection, batch consistency, sterilization validation review, and signal detection in post-market data. For health systems and payers, machine learning models can combine claims, imaging, comorbidity, and procedural data to identify patients at higher risk of restenosis or reintervention, supporting evidence-based device selection while preserving clinician oversight and regulatory compliance.

Key Regional Insights: Asia-Pacific, North America, Europe, Latin America, Middle East, and Africa

Asia-Pacific is a high-priority growth region because China, India, Japan, South Korea, and Australia face rising burdens of diabetes, aging-related vascular disease, and endovascular procedure demand. Japan and Australia have mature reimbursement pathways, experienced interventional specialists, and high-quality clinical governance, while China and India are expanding domestic manufacturing, hospital access, vascular training, and clinical adoption across large urban centers.

North America remains an evidence-driven market led by the United States, where FDA-approved drug-coated balloon indications, outpatient endovascular programs, and value-based care scrutiny shape purchasing decisions. Canada follows a more centralized health technology assessment and provincial reimbursement pathway, favoring devices with strong clinical, safety, and economic evidence.

Europe continues to be a major innovation and clinical evidence hub, but the EU Medical Device Regulation has increased documentation, clinical evaluation, notified body review, and post-market performance requirements. Latin America is led by Brazil and Mexico, where private hospitals adopt advanced endovascular devices faster than public systems, while reimbursement variability affects broader access. The Middle East, especially GCC healthcare systems, is investing in cardiovascular infrastructure and diabetes-related vascular care, while Africa remains constrained by uneven catheterization laboratory capacity, specialist availability, reimbursement gaps, and affordability.

Key Group Insights: ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN markets are becoming more relevant as Thailand, Malaysia, Singapore, Indonesia, Vietnam, and the Philippines expand cardiovascular and peripheral vascular intervention services. Adoption is strongest where tertiary hospitals, private insurance, and specialist training support complex endovascular care, while price sensitivity and public procurement constraints continue to influence access.

The GCC benefits from national healthcare investment, high diabetes prevalence, and expansion of vascular centers, making evidence-based premium devices attractive when supported by procurement value analysis and clinician training. The European Union remains highly regulated under MDR, favoring suppliers with rigorous clinical evidence, UDI readiness, quality management discipline, and post-market surveillance systems.

BRICS countries represent large-volume opportunity but require localized pricing, registration expertise, domestic partnership strategies, and physician education. The G7 markets are characterized by advanced intervention capacity, mature payer systems, strong clinical trial ecosystems, and stricter evidence standards. NATO-aligned markets overlap significantly with North America and Europe, where supply chain resilience, regulatory compliance, cybersecurity, traceability, and trusted manufacturing networks are increasingly important for medical device procurement.

Key Country Insights Across Major Drug Eluting Balloon Markets

The United States is the largest strategic market due to FDA-cleared and FDA-approved device pathways, robust specialist adoption, extensive clinical trial activity, and strong outpatient vascular intervention activity. Canada emphasizes clinical evidence and provincial budget impact, while Mexico's adoption is concentrated in private hospitals and major public referral centers. Brazil is Latin America's most important country market because of its population scale, established interventional cardiology base, growing endovascular capability, and concentration of advanced care in major metropolitan regions.

In Europe, the United Kingdom prioritizes National Health Service value, clinical guidance, and procurement efficiency. Germany benefits from a large hospital base and advanced cardiovascular intervention capacity, while France, Italy, and Spain combine specialist expertise with reimbursement pressure and stronger demand for real-world evidence. Russia remains a complex market shaped by localization, procurement policy, registration requirements, and geopolitical constraints.

China is scaling domestic innovation, hospital adoption, and regulatory modernization, India is driven by vascular disease burden, diabetes prevalence, affordability needs, and expanding private healthcare capacity, and Japan is characterized by high-quality evidence expectations, advanced physician training, and disciplined reimbursement review. Australia has a mature specialist environment and structured reimbursement evaluation, while South Korea combines strong hospital technology adoption, physician expertise, and an export-oriented medical device ecosystem.

Actionable Recommendations for Drug Eluting Balloon Industry Leaders

Industry leaders should prioritize differentiated clinical evidence, not only product availability. Trials and registries should focus on lesion-specific outcomes, durability, freedom from target lesion revascularization, limb outcomes, wound healing, patient-reported measures, and real-world performance in diabetes, chronic kidney disease, long lesions, calcified disease, below-the-knee disease, and in-stent restenosis.

Manufacturers should invest in AI-enabled quality systems, coating consistency analytics, digital physician training, and post-market surveillance. Commercial teams should align claims with approved indications, build health economic dossiers for payers, strengthen adverse-event reporting, and localize strategies for MDR-regulated Europe, FDA-driven North America, fast-growing Asia-Pacific, and price-sensitive emerging markets.

Research Methodology

This executive summary is based on structured secondary research and evidence triangulation across regulatory communications, clinical trial publications, peer-reviewed vascular and interventional cardiology literature, medical society guidance, reimbursement context, public regulatory filings, and public health data related to peripheral artery disease, coronary restenosis, diabetes, chronic kidney disease, and endovascular procedures.

The methodology emphasizes verified and reproducible sources, including FDA safety communications, European regulatory requirements, published randomized studies, meta-analyses, post-market registries, and country-level healthcare infrastructure indicators. Insights are synthesized to identify market direction, clinical relevance, regional adoption patterns, technology shifts, and strategic implications for drug eluting balloon stakeholders while avoiding unsupported sizing, share, or forecasting assumptions.

Conclusion

Drug eluting balloons are positioned at the intersection of minimally invasive vascular therapy, device-based drug delivery, and evidence-driven healthcare purchasing. Their central value proposition is the ability to inhibit restenosis while avoiding permanent implants, which remains relevant in peripheral and selected coronary interventions.

Future market leadership will depend on proven outcomes, disciplined regulatory execution, coating and drug-delivery innovation, physician education, and real-world evidence generation. Companies that combine clinical credibility with scalable manufacturing, digital surveillance, compliant market access, and localized adoption strategies are best positioned to compete as the drug eluting balloon market evolves.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Drug Eluting Balloon Market, by Drug Type

• 7.1. Paclitaxel-Coated
• 7.2. Sirolimus-Coated

8. Drug Eluting Balloon Market, by Product Type

• 8.1. Conventional Balloon
• 8.2. Specialty Balloon

9. Drug Eluting Balloon Market, by Application

• 9.1. Coronary Artery Disease
  • 9.1.1. De Novo Lesion
  • 9.1.2. In-Stent Restenosis
• 9.2. Peripheral Artery Disease
  • 9.2.1. Below Knee
  • 9.2.2. Femoropopliteal

10. Drug Eluting Balloon Market, by End User

• 10.1. Ambulatory Surgical Center
• 10.2. Clinic
• 10.3. Hospital

11. Drug Eluting Balloon Market, by Distribution Channel

• 11.1. Direct
• 11.2. Distributor

12. Drug Eluting Balloon Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Drug Eluting Balloon Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Drug Eluting Balloon Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories
• 16.2. B. Braun Melsungen AG
• 16.3. Balton Sp. z o. o.
• 16.4. Bayer AG
• 16.5. Becton, Dickinson and Company
• 16.6. Biosensors International Group, Ltd.
• 16.7. Biotronik SE & Co. KG
• 16.8. Boston Scientific Corporation
• 16.9. Cardionovum GmbH
• 16.10. Concept Medical
• 16.11. Cook Medical, Inc.
• 16.12. Eurocor Tech GmbH
• 16.13. Invamed
• 16.14. iVascular S.L.U.
• 16.15. Johnson & Johnson Services, Inc.
• 16.16. Koninklijke Philips N.V.
• 16.17. Laborie Medical Technologies, Inc.
• 16.18. Lepu Medical Technology
• 16.19. M.A. Med Alliance SA by Cordis Corporation
• 16.20. Medtronic PLC
• 16.21. SurModics, Inc.
• 16.22. Terumo Corporation
• 16.23. Wellinq
• 16.24. Zylox-Tonbridge Medical Technology Co., Ltd.